FDA Warning Letters

OSINT, Standards

Free
No Download/Install required
No registration

https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters

The FDA Warning Letters database provides a public record of formal notifications issued to companies and individuals for significant violations of federal regulations. These letters detail specific deviations identified during agency inspections, such as failures in Current Good Manufacturing Practice (CGMP), inadequate quality system controls, and unauthorized product claims. The service includes a searchable interface that allows users to filter enforcement actions by company name, issuing office, and date, providing transparency into the agency’s regulatory focus and the technical failures that trigger legal escalations across the pharmaceutical, medical device, and food industries.

Both latest and the 3700+ previous letters, giving much details about your current or potential suppliers … or competitors.

A must for those in the medical or food industry. Put some alert system on this page or subscribe to their newsletter on the bottom of their page.

Quality and manufacturing professionals apply this data to perform gap analyses and proactive risk assessments by benchmarking internal processes against documented industry failures. By analyzing citations related to data integrity, sterilization validation, and equipment calibration, engineers can refine standard operating procedures to mitigate compliance risks before they result in enforcement actions.

Disciplines: Regulatory affairs, Pharmaceutical development, Medical devices, Quality assurance, Food safety, Legal compliance.

Free alternative to Redica Systems, Citeline.

FDA Warning Letters compared with Redica Systems and Citeline (now Citeline)
FDA Warning Letters	Redica Systems	Citeline (now Citeline)
Nature of the source: The FDA publishes the warning letters itself, so this is the primary record. The table lists posted date, issue date, company, issuing office, subject, response or closeout flags and an excerpt, with a link to each letter.	Nature of the source: Redica is a commercial regulatory intelligence platform. Its products are Regulatory Intelligence, Inspection Intelligence, Site Intelligence and Postmarket Intelligence, which link inspections, enforcement, recalls and adverse events to sites and suppliers.	Nature of the source: Citeline supplied intelligence, data and software for clinical trials, drug development and regulatory compliance. In the regulatory area its Pink Sheet is described as pharmaceutical news and regulatory trend analysis, so it interprets events rather than hosting the FDA letters.
Coverage: Only letters issued by the FDA are listed. The page carries a note that matters described in a letter may have been subject to later interaction, which can change the regulatory status of the issues.	Coverage: Redica states that it tracks regulatory changes from 250+ regulators and standards bodies and holds 170K+ inspection documents. Earlier material from the same company names Form 483s, establishment inspection reports and warning letters as FDA sources.	Coverage: Coverage is oriented to the pharmaceutical industry. In 2022 the company described its clinical trial data as covering more than 375,000 trials in 180 countries. Warning letter coverage is not stated on the pages checked.
Search and data access: Filters are issuing office, letter issue date, posted date, year, and letters with a response or closeout, plus a keyword box. Two XLSX downloads, email updates and links to FDA RSS feeds are provided. The page showed content current as of 13 October 2026.	Search and data access: Access is through the Redica App, an API and integrated solutions. The site does not describe a self-service search of the raw letters.	Search and data access: Each Citeline product has its own login page. The product login page lists Pink Sheet under regulatory and compliance, and a contact page is the route for enquiries.
Access and cost model: Free public access, with no account needed to read the letters. Email subscription is optional.	Access and cost model: Access starts with a personalized demo. Pricing is not published on the pages checked, so the model is vendor quoted.	Access and cost model: Commercial products reached through separate product logins and a contact form. Pricing is not published on the pages checked.
Status and naming: Letters and their closeout status are updated on the same listing.	Status and naming: The site lists four intelligence products on one platform.	Status and naming: The business was renamed Citeline on 22 June 2022, after Warburg Pincus bought it from Informa. Citeline later merged with Norstella and now describes itself as a Norstella company, so the Pharma Intelligence name is historical.